Trinity Biotech (TRIB) investor relations material

Company overview and business model

• Commercial-stage biotechnology company focused on diabetes management and human diagnostics, including wearable biosensors.

• Develops, acquires, manufactures, and markets diagnostic systems for point-of-care and clinical labs, recently expanding into wearable biosensors with the acquisition of Waveform Technologies assets.

• Products detect infectious diseases and quantify biomarkers like Hemoglobin A1c; sold directly in the US, Brazil, UK, Germany, France, and via distributors in ~100 countries.

• Incorporated in Ireland in 1992, with principal offices in Bray, County Wicklow, Ireland, and North American HQ in Jamestown, NY.

Financial performance and metrics

• As of December 31, 2025, cash and cash equivalents were $5.1M (actual) and $7.6M (as adjusted).

• Total debt stood at $124.6M (actual) and $130.9M (as adjusted), with a negative shareholders' equity of $71.98M.

• Excludes significant potential dilution from options, warrants, and convertible notes representing hundreds of millions of additional shares.

Use of proceeds and capital allocation

• May receive up to $25M in gross proceeds from the sale of ADSs to the Selling Securityholder under the Purchase Agreement.

• Proceeds intended for operating expenses, working capital, strategic, and general corporate purposes; management has broad discretion over use.

• No proceeds from the resale of ADSs by the Selling Securityholder.